Gareth R Davies1, Matthew Lawrence1, Suresh Pillai2, Gavin M Mills2, Robert Aubrey2, Dafydd Thomas3, Rhodri Williams4, Keith Morris5, Phillip Adrian Evans6. 1. Haemostasis Biomedical Research Unit (HBRU), Morriston Hospital, Swansea, UK; College of Medicine, Swansea University, Swansea, UK. 2. Emergency Department, Morriston Hospital, ABM University Health Board, Swansea, UK. 3. Cardiac Intensive Care Unit, Morriston Hospital, ABM University Health Board, Swansea, UK. 4. College of Engineering, Swansea University, Swansea, UK. 5. School of Applied Sciences, Cardiff Metropolitan University, Cardiff, UK. 6. Haemostasis Biomedical Research Unit (HBRU), Morriston Hospital, Swansea, UK; College of Medicine, Swansea University, Swansea, UK; Emergency Department, Morriston Hospital, ABM University Health Board, Swansea, UK. Electronic address: phillip.evans2@wales.nhs.uk.
Abstract
PURPOSE: The study purpose was to define changes in coagulation across the sepsis spectrum using rotational thromboelastometry (ROTEM). METHODS: Sepsis patients were recruited on admission to the Emergency Department and Intensive Care Units of a large teaching hospital in Wales. ROTEM markers of clot development and fibrinolysis were determined, as well as standard coagulation markers. A healthy control group matched for age and gender was also recruited (n=44). RESULTS: 100 patients were recruited (50 sepsis, 20 severe sepsis and 30 septic shock). Maximum clot firmness was significantly higher in the sepsis (p<0.001) and severe sepsis (p=0.012) groups than the healthy control (71.6±4.5 and 70.4±4.1 vs 64.4 respectively). In septic shock there was prolonged clot development; however, maximum clot firmness remained normal. Fibrinolytic function was significantly impaired in septic shock, which was also significantly associated with 28-day mortality (p<0.001). CONCLUSIONS: ROTEM indicated significantly enhanced clot structural development in sepsis and severe sepsis, which could be indicative of a hypercoagulable phase. In septic shock, despite there being a prolongation of clotting pathways and impaired fibrinolysis, clot mass was comparably normal, suggestive of the development of a clot with healthy characteristics.
PURPOSE: The study purpose was to define changes in coagulation across the sepsis spectrum using rotational thromboelastometry (ROTEM). METHODS:Sepsispatients were recruited on admission to the Emergency Department and Intensive Care Units of a large teaching hospital in Wales. ROTEM markers of clot development and fibrinolysis were determined, as well as standard coagulation markers. A healthy control group matched for age and gender was also recruited (n=44). RESULTS: 100 patients were recruited (50 sepsis, 20 severe sepsis and 30 septic shock). Maximum clot firmness was significantly higher in the sepsis (p<0.001) and severe sepsis (p=0.012) groups than the healthy control (71.6±4.5 and 70.4±4.1 vs 64.4 respectively). In septic shock there was prolonged clot development; however, maximum clot firmness remained normal. Fibrinolytic function was significantly impaired in septic shock, which was also significantly associated with 28-day mortality (p<0.001). CONCLUSIONS: ROTEM indicated significantly enhanced clot structural development in sepsis and severe sepsis, which could be indicative of a hypercoagulable phase. In septic shock, despite there being a prolongation of clotting pathways and impaired fibrinolysis, clot mass was comparably normal, suggestive of the development of a clot with healthy characteristics.
Authors: Annalisa Boscolo; Luca Spiezia; Elena Campello; Elisabetta Maria Consolaro; Carlo Ori; Paolo Simioni Journal: Intern Emerg Med Date: 2019-07-02 Impact factor: 3.397
Authors: Lou M Almskog; Agneta Wikman; Jonas Svensson; Matteo Bottai; Mariann Kotormán; Carl-Magnus Wahlgren; Michael Wanecek; Jan van der Linden; Anna Ågren Journal: TH Open Date: 2021-12-21
Authors: Matthew J Lawrence; Vanessa Evans; Janet Whitley; Suresh Pillai; Phylip R Williams; James Coulson; Manju Krishnan; Peter Slade; Kieron Power; Roger H K Morris; Phillip A Evans Journal: Pharmacol Res Perspect Date: 2022-04
Authors: Jay S Raval; Allison E Burnett; Marian A Rollins-Raval; Joseph R Griggs; Lizabeth Rosenbaum; Nathan D Nielsen; Michelle S Harkins Journal: Transfusion Date: 2020-05-22 Impact factor: 3.337